UNSPSC 51352012: Ethinyl estradiol or ethinylestradiol

This classification denotes a therapeutic estradiol, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 423D2T571U. European Medicines Agency schedules Ethinyl estradiol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07277MIG. Ethinylestradiol generally arises in the molecular formula C20H24O2. The term 'ethinylestradiol' is a European Medicines Agency European Public Assessment Report System designation.

ETHINYLESTRADIOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Ethinyl estradiol bears US NLM identifiers UMLS ID C0015011 and NCI Concept Code C486. SMILES: OC1(C2(C(C3C(CC2)c2c(CC3)cc(O)cc2)CC1)C)C#C.

UNSPSC 51352012 Ethinyl estradiol or ethinylestradiol is a Commodity code covering a specific pharmaceutical active ingredient used primarily in hormonal contraceptive formulations and hormone replacement therapies. State and local governments procure this product as part of broader generic pharmaceutical supply contracts, typically through multi-state cooperative purchasing vehicles that consolidate demand across health departments, correctional facilities, and other government healthcare operations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represents the primary issuing body active under this code, purchasing on behalf of participating state agencies and local health systems across multiple jurisdictions including Minnesota and Oregon. Vendors responding to this category must meet rigorous pharmaceutical manufacturing and supply chain compliance standards, including current Good Manufacturing Practices (cGMP) certification and Drug Supply Chain Security Act (DSCSA) compliance, and must maintain contractual relationships with authorized wholesalers such as AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC to distribute products through established chargeback systems.

MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) drives current activity under this code, with awards effective July 1, 2026 for a two-year initial term and optional extensions through June 30, 2028. Pricing evaluation weighs competitiveness most heavily at 75 percent of the score, with fixed pricing, EDI capability, administrative fee compliance, and format adherence each contributing smaller percentages. Vendors must carry comprehensive insurance including commercial general liability of $5 million per occurrence and professional liability of $2 million, and products must meet FDA requirements with a minimum one-year expiration date from manufacture and six-month shelf life guarantee. The solicitation applies to Minnesota, Oregon, and other MMCAP member jurisdictions; no specific geographic concentration or additional recent opportunities under this code are evident from the source material.